As other major pharma players like Merck (NYSE:MRK) and Johnson & Johnson (NYSE:JNJ) vow to limit annual price hikes, a report by the Financial Times found that Pfizer (NYSE:PFE) has raised prices on 91 drugs by an average of 21% in 2017. The most recent price hike at the start of June was the company’s 2nd for […]
Marathon Pharmaceuticals
Amid drug-pricing criticism, industry trade group ousts members
The pharmaceutical industry’s trade group ousted 22 companies earlier this week after it revised membership rules. The move comes as lawmakers in Washington have pressed the pharma industry about U.S. drug prices. The updated membership rules for the Pharmaceutical Research and Manufacturers of America (PhRMA) group mandates that members spend at least $200 million each year […]
UPDATED: Mallinckrodt, Marathon leave industry trade group over drug pricing controversy
Updated to include a statement from Mallinckrodt regarding its membership with PhRMA. Marathon Pharmaceuticals reportedly withdrew from the drug industry’s lobbying group yesterday following controversy over its pricey drug, Emflaza. Pharmaceutical Research and Manufacturers of America (PhRMA) began reconsidering its membership criteria as reports revealed a number of drugmakers hiking the prices of their products. […]
Trump drug pricing tweet sends pharma stocks down
Shares in Pfizer (NYSE:PFE), Merck (NYSE:MRK) and Amgen (NSDQ:AMGN) fell slightly this morning after President Donald Trump tweeted that he was working on a “new system” to lower drug prices. “I am working on a new system where there will be competition in the Drug Industry,” he wrote. “Pricing for the American people will come way down!” […]
Report finds pharma companies limited January list price hikes
Drug-makers didn’t raise list prices for as many drugs in January compared to last year and they initiated fewer hikes of 10% or more, according to analysis by Raymond James & Associates. Although 5.5% of price increases reached the 10% level in January this year, 15% did last year and 20% did 2 years ago. […]
Marathon hikes MD drug price 70x to $89k a year
After winning FDA approval for its muscular dystrophy drug last week, Marathon Pharmaceuticals set the drug’s list price at $89,000 a year – 50 to 70 times greater than what most U.S. patients have paid for decades by importing the drug from Europe. Marathon’s drug is a corticosteroid, deflazacort, that has been shown to improve muscular […]
